Literature DB >> 6709073

Carboxy terminus of vasopressin required for activity but not binding.

M Manning, A Olma, W Klis, A Kolodziejczyk, E Nawrocka, A Misicka, J Seto, W H Sawyer.   

Abstract

Vasopressin antagonists are valuable pharmacological tools for investigating physiological and behavioural functions of the nonapeptide arginine-vasopressin (AVP). The removal of glycinamide from the carboxy terminus of AVP drastically reduces its characteristic vasopressor and antidiuretic activities. In contrast to this we show here that removal of the carboxy-terminal glycinamide or the glycine at position 9 from several vasopressin antagonists makes little difference to their ability to block vasopressor and antidiuretic responses to AVP. These data demonstrate the critical structural requirements of the carboxy-terminal position for receptor activation, in contrast to the lack of such requirements for receptor binding. They also provide an avenue to a wide variety of antagonists substituted at the carboxy terminus (for example radiolabelled derivatives and affinity ligands) and suggest clues for the development of more potent and/or selective antagonists.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6709073     DOI: 10.1038/308652a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  3 in total

1.  Characterization of specific V1a vasopressin-binding sites on a rat mammary-tumour-cell line.

Authors:  G Guillon; C J Kirk; M N Balestre
Journal:  Biochem J       Date:  1986-11-15       Impact factor: 3.857

2.  Peptidylglycine alpha-amidating monooxygenase activity and TRH and CRF biosynthesis. Role of copper.

Authors:  P Giraud; J Y Maltèse; F Boudouresque; P Salers; L Ouafik; M Renard; F Pelen; C Oliver
Journal:  Biol Trace Elem Res       Date:  1992 Jan-Mar       Impact factor: 3.738

3.  Development of a human vasopressin V1a-receptor antagonist from an evolutionary-related insect neuropeptide.

Authors:  Maria Giulia Di Giglio; Markus Muttenthaler; Kasper Harpsøe; Zita Liutkeviciute; Peter Keov; Thomas Eder; Thomas Rattei; Sarah Arrowsmith; Susan Wray; Ales Marek; Tomas Elbert; Paul F Alewood; David E Gloriam; Christian W Gruber
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.